9 nominees · 4 ballot items.
Elect nine directors; ratify Ernst & Young LLP as independent auditor for 2026; approve, on an advisory (non-binding) basis, the Company’s executive compensation (say-on-pay); and approve an amendment and restatement of the Employee Stock Purchase Plan to add 3,000,000 shares for issuance.
Elect the nine nominees named in the proxy statement to serve as directors until the 2027 Annual Meeting.
Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2026.
Non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in this proxy statement.
This is an advisory (non-binding) 'say-on-pay' proposal asking shareholders to approve the Company’s executive compensation as disclosed in the proxy, including the Compensation Discussion and Analysis and accompanying tables. Management frames the program as heavily performance-linked — a substantial majority of target compensation is tied to long-term equity and annual incentive metrics (Operating EBITDA, a margin measure, and internal revenue growth) and a sustainability scorecard modifier — with PSUs linked to three-year TSR and cash-flow metrics and stock options to support long-term stock-price appreciation. The Board emphasizes governance safeguards: stock ownership guidelines, clawback policies (including adherence to the NYSE-mandated clawback), a severance limitation policy, and limits on certain tax gross-ups and death benefits. The justification also cites consistent peer benchmarking, the MD&C Committee’s use of an independent consultant, and recent payout outcomes (PSU payouts above target for the 2023-2025 period) as evidence of alignment of pay and performance. Critically, the vote is advisory and will not automatically change pay arrangements, but the MD&C Committee says it will consider shareholder feedback when setting future compensation. Potential investor concerns include dilution from equity awards, the size and structure of CEO long-term awards (notably a large target dollar value), and use of certain discretion (e.g., calculation adjustments and sustainability modifiers) that could be seen as attenuating formulaic linkage between pay and results. The Board argues such discretion and adjustments are applied to ensure incentive metrics reflect underlying business performance and exclude one-time or acquisition-related distortions (e.g., Stericycle integration adjustments), while preserving incentives for strategic investments. In evaluating the proposal, an analyst should weigh robust structural alignment (high percent of pay at risk, multi-year performance metrics, clawbacks, ownership guidelines) against areas where discretion and adjustments could be material, and consider recent realized payouts and TSR relative performance which management highlights as supportive of its approach.
Approve amendment and restatement of the ESPP to authorize an additional 3,000,000 shares of Common Stock for issuance under the plan.
Management seeks shareholder approval to amend and restate the Employee Stock Purchase Plan to add three million shares to the pool available for issuance. The Company states that as of January 1, 2026 approximately 49,266 employees were eligible to participate, ~949,504 shares remained available, and annual ESPP purchases over recent years have been ~400–470k shares, motivating the additional authorization to continue broad-based employee participation. The ESPP terms are employee-friendly (6‑month offering periods; purchase price equal to 85% of fair market value on the last business day of each offering period) which supports employee retention and ownership but also creates recurring issuance and accounting expense. Management highlights that the incremental 3,000,000 shares represent less than 1% of outstanding common stock, limiting dilution; they will register shares on Form S-8 if approved. The Board’s rationale emphasizes workforce engagement and the alignment of employees with long-term shareholder interests through ownership, noting the plan’s eligibility and limits (1–10% payroll deductions, $21,250 annual payroll deduction cap, $25,000 purchase value annual cap per Section 423) that constrain over-allocation to any single employee. From a governance perspective, an analyst should weigh the relatively small dilutive impact against the value of broad-based ownership for retention and cultural alignment, and consider the plan’s accounting/expense treatment and historical uptake rates. The proposal is management-sponsored and routine in nature for large companies with active employee purchase programs; key risks are future dilution if the plan continues to be heavily used, and the potential for concentrated purchases by certain employees subject to plan limits. Overall, the Board recommends approval based on promoting employee engagement and continuing an established benefit program while keeping the incremental share request modest relative to the company’s outstanding float.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | GATES FOUNDATION TRUST | 6.88% | 27,642,344 | $6.4B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6.27% | 25,169,513 | $5.8B |
| 3 | STATE STREET CORP | 4.36% | 17,501,722 | $4.0B |
| 4 | BlackRock, Inc. | 2.94% | 11,798,686 | $2.7B |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.55% | 10,236,665 | $2.4B |
| 6 | Capital Research Global Investors | 2.17% | 8,732,043 | $2.0B |
| 7 | BlackRock, Inc. | 2.02% | 8,119,308 | $1.9B |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.00% | 8,012,075 | $1.8B |
| 9 | PARNASSUS INVESTMENTS, LLC | 1.24% | 4,981,578 | $1.1B |
| 10 | AMERIPRISE FINANCIAL INC | 0.99% | 3,988,886 | $917M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.